Evidence map›Paper›PMID 40440464›Full record

ArticleNeuro-oncology2025

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.

Aleksandra B Lasica, Zhou Lan, Julie J Miller, Albert Jiao, Ian Pan, Loai Aker, Prem Prabhakar, Julia Japo, Alyssa Russ, Catharina Westergaard and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Current and emerging therapies in IDH-mutant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Aleksandra B LasicaHarvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0002-9739-5103
Zhou LanCenter for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, USA.
Julie J MillerPappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Albert JiaoDivision of Neuroradiology, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Ian PanDivision of Neuroradiology, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Loai AkerDivision of Neuroradiology, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Prem PrabhakarDivision of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Julia JapoDivision of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Alyssa RussCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Catharina WestergaardCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elisa AquilantiHarvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0002-1343-5017
Ugonma ChukwuekeHarvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0003-0598-9535
L Nicolas Gonzalez CastroDepartment of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
J Ricardo McFaline FigueroaDepartment of Neurology, Grossman School of Medicine, New York University, New York, NY, USA.
Eudocia Quant LeeHarvard Medical School, Harvard University, Boston, MA, USA.
Lakshmi NayakHarvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0003-2725-8717
Rameen BeroukhimHarvard Medical School, Harvard University, Boston, MA, USA.
Tracy T BatchelorDepartment of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Daniel P CahillDepartment of Neurosurgery, Mass General Brigham, Boston, MA, USA.ORCID 0000-0003-2552-6546
Vihang NakhatePappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-2941-9740
Tyler LanmanPappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Juan Pablo OspinaPappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Natalie StecPappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Ruchit V PatelDepartment of Neurosurgery, Mass General Brigham, Boston, MA, USA.
David M MeredithDivision of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Wenya Linda BiDepartment of Neurosurgery, Mass General Brigham, Boston, MA, USA.
David A ReardonHarvard Medical School, Harvard University, Boston, MA, USA.
Keith L LigonDivision of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Raymond Y HuangDivision of Neuroradiology, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Patrick Y WenHarvard Medical School, Harvard University, Boston, MA, USA.
Gilbert YoussefHarvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0001-6109-7692

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAstrocytoma, isocitrate dehydrogenase-mutant, WHO grade 4 (Astro4), is a new tumor type in the 2021 WHO classification of central nervous system tumors that has been poorly characterized in the literature. This study evaluates predictors of prognosis in a large cohort of newly diagnosed Astro4.

methodsWe retrospectively identified 128 consecutive adult patients who presented with an initial diagnosis of Astro4 at Dana-Farber Cancer Institute and Massachusetts General Hospital between 2010 and 2021. Clinical, molecular, and radiological characteristics were recorded, and their associations with overall survival (OS) and progression-free survival (PFS) were measured by log-rank test and Cox proportional hazards model.

resultsThe median age at diagnosis was 37.1 years, and 61.7% were men. The median OS was 5.9 years (95% confidence interval, 4.4-7.3), while the median PFS was 2.7 years (1.8 -3.6). Age ≥ 50 and homozygous CDKN2A/B deletion were independent negative prognosticators of OS on univariate and multivariate analyses (hazard ratio [HR], 2.21 [1.16-4.21], P = .019; HR, 2.61 [1.27-5.38], P = .013). Maximal resection of enhancing disease was associated with longer PFS on univariate and multivariate analyses (HR, 0.48 [0.26-0.87], P = .019). There were no significant differences in OS or PFS based on MGMT promoter methylation status, T2/FLAIR extent of resection, T2/FLAIR mismatch, radiological pseudoprogression, or enhancement on the pre-operative scan.

conclusionsOur study comprehensively characterizes a large cohort of newly diagnosed patients with Astro4, emphasizing the prognostic value of CDKN2A/B deletion, age, and the extent of resection of enhancing disease in these patients.

Indexed as

AstrocytomaBiomarkers, TumorBrain NeoplasmsIsocitrate DehydrogenaseMutationAdolescentAdultAgedDNA MethylationFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorIsocitrate DehydrogenaseastrocytomaCDKN2A/B deletionIDH-mutantprognosisWHO Grade 4

Identifiers

PMID40440464
PMCPMC12526062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.